Skip to main content

Table 1 Baseline demographics and clinical characteristics of the patients (N = 132)

From: Tumor Hypervascularity and hand-foot-skin reaction predict better outcomes in combination treatment of TACE and Sorafenib for intermediate hepatocellular carcinoma

Characteristics Number (%) / mean ± S.D. / median [IQR]
Age at start (year) 53 ± 12.1/53 [43–61]
Gender
 men 112 (84.8%)
 women 20 (15.2%)
Etiology
 Hepatitis B 109 (82.6%)
 Hepatitis C 6 (4.5%)
 Others 17 (12.9%)
Child-Pugh class
 A 124 (93.9%)
 B 8 (6.1%)
Performance status  
 ECOG 0 85 (64.4%)
 ECOG 1 47 (35.6%)
BCLC stage
 A 10 (7.6%)
 B 75 (56.8%)
 C 47 (35.6%)
Tumor burden
 Tumor size (cm) 8.0 ± 3.7/7.1 [5.2–9.8]
 No. of HCC nodules 2.1 ± 1.9/1 [1–2.25]
 AFP (ng/dl) 1188.4 ± 2774.7/230.8 [8.7–7713.5]
 Leukocyte (×10E9/L) 5.9 ± 2.7/5.3 [4.2–6.9]
 Hemoglobin (g/L) 136.5 ± 20.6/138.0 [126.0–192.5]
 Platelets (×10E9/L) 150.1 ± 89.3/134.0 [91.0–192.3]
 International normalized ratio 1.16 ± 0.13/1.10 [1.02–1.17]
 Alanine aminotransferase (U/L) 45.6 ± 32.3/37 [24.5–57.0]
 Aspartate aminotransferase (U/L) 53.1 ± 32.7/40.5 [30–69.5]
 Albumin (g/L) 39.7 ± 5.3/39.8 [36.6–42.5]
 Total bilirubin (μmol/L) 16.6 ± 6.8/15.3 [11.6–19.6]
 Urea nitrogen (mmol/L) 5.2 ± 1.7/4.8 [4.2–6]
 Serum creatinine (umol/L) 84.2 ± 15.9/82.5 [73.8–95.0]
  1. Abbreviations: S.D. standard deviation, IQR interquartile range, ECOG Eastern Cooperative Oncology Group, BCLC Barcelona Clinic Liver Cancer, AFP alpha-fetoprotein